Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma


Por: Sorigue, M, Sancho, JM, Pineda, A, Garcia, O, Lopez, D, Moreno, M, Tapia, G, Batlle, M, Ferra, C, Vives, S, Ibarra, G, Feliu, E and Ribera, JM

Publicada: 1 jul 2017
Resumen:
Nephrotoxicity is a wellknown side effect of platinumbased chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate < 60 mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2yr OS probability [ 95% CI]: 88% [ 77%99%] vs. 50% [ 22%78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAPinduced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.

Filiaciones:
:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

Pineda, A:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

Garcia, O:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Hosp Badalona Germans Trias & Pujol, ICO Badalona, ICO Pharm Unit, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Dept Pathol, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain

:
 Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Dept Hematol,ICO Badalona, Barcelona, Spain
ISSN: 01452126





Leukemia Research
Editorial
Elsevier Ltd., THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 58 Número:
Páginas: 98-101
WOS Id: 000405375300014
ID de PubMed: 28521176

MÉTRICAS